Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report), Eledon Pharmaceuticals (ELDN – Research Report) and Legend Biotech ...

DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 ...

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes just unveiled an announcement. Alkermes plc shareholders, during their 2024 Annual Meeting, approved key amendments to the company’s stock plan, including a substantial ...

Investors in Alkermes plc ALKS need to pay close attention to the stock based on moves in the options market lately. That is because the Aug 16, 2024 $34 Call had some of the highest implied ...

Over the past 15 years, on average, racial and ethnic diversity in multiple US regions has increased by 1% to 5%. JAMA study ...

The annual Business Courier Best Places to Work program recognizes Greater Cincinnati companies that rate highest for employee satisfaction. Meet the 75 finalists here. The Business Courier has named ...

Baird raised the price target for the Alkermes plc (NASDAQ:ALKS) stock to “an Outperform”. The rating was released on March 19, 2024, according to finviz. The research report from JP Morgan has ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th ...